2025
Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severity
2024
Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review
Besteman S, Bogaert D, Bont L, Mejias A, Ramilo O, Weinberger D, Dagan R. Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review. The Lancet Respiratory Medicine 2024, 12: 915-932. PMID: 38991585, DOI: 10.1016/s2213-2600(24)00148-6.Peer-Reviewed Original ResearchRespiratory syncytial virusChildhood respiratory infectionsRespiratory infectionsSyncytial virusStreptococcus pneumoniaeRespiratory syncytial virus vaccineLower respiratory tract infectionsRespiratory tract infectionsSystematic reviewGlobal health burdenYears of ageRSV hospitalisationTract infectionsPneumococcal vaccineSevere diseaseGlobal morbidityEpidemiological associationMonoclonal antibodiesPathogen-pathogen interactionsPneumococciInfectionHealth burdenPathogenesisHost modulationApproaches to disease prevention
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply